Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 28

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 28
---
 risks related to the Group's products;

- the risk of failure to achieve strategic plans or meet targets or expectations;

- the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business;

- the risk of failure in internal control, financial reporting or the occurrence of fraud;

- the risk of unexpected deterioration in the Group's financial position;

- the risk of foreign exchange rate movements impacting our financial condition or results of operations; and

- the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition.

Glossary

1L, 2L, etc First line, second line, etc

AAAAI American Academy of Allergy, Asthma, and Immunology

ACC American College of Cardiology

aHUS Atypical haemolytic uraemic syndrome

AKT Serine/threonine protein kinase

ALK Anaplastic lymphoma kinase gene

ASCO American Society of Clinical Oncology

ATTR / -CM / -PN Transthyretin-mediated amyloid / cardiomyopathy / polyneuropathy

ATTRv / -CM / -PN Hereditary transthyretin-mediated amyloid / cardiomyopathy / polyneuropathy

BTC Biliary tract cancer

BTKi Bruton tyrosine kinase inhibitor

CDK4 Cyclin-dependent kinase 4

CER Constant exchange rates

CHMP Committee for Medicinal Products for Human Use (EU)

CI Confidence interval

CLL Chronic lymphocytic leukaemia

CN China

CRSwNP Chronic rhinosinusitis with nasal polyps

CVRM Cardiovascular, Renal and Metabolism

EBITDA Earnings before interest, tax, depreciation and amortisation

EFS Event free survival

EGFR / m Epidermal growth factor receptor gene / mutation

EGPA Eosinophilic granulomatosis with polyangiitis

EM Emerging Markets

EPS Earnings per share

ESR1 / m Oestrogen Receptor 1 gene / mutation

EVH Extravascular haemolysis

FDC Fixed dose combination

FLOT A treatment regimen: fluorouracil, oxaliplatin and docetaxel

GAAP Generally Accepted Accounting Principles

GEJ Gastro oesophageal junction

GI Gastrointestinal

gMG Generalised myasthenia gravis

GU Genito